Advertisement

Hormones

, Volume 12, Issue 3, pp 405–416 | Cite as

Sex steroids and sex hormone-binding globulin in postmenopausal women with nonalcoholic fatty liver disease

  • Stergios A. PolyzosEmail author
  • Jannis Kountouras
  • Agathocles Tsatsoulis
  • Efthimia Zafeiriadou
  • Evangelia Katsiki
  • Kalliopi Patsiaoura
  • Christos Zavos
  • Vasiliki V. Anastasiadou
  • Aristidis Slavakis
Research paper

Abstract

OBJECTIVE

The evaluation of serum sex steroids and sex hormone-binding globulin (SHBG) levels in postmenopausal women with nonalcoholic fatty liver disease (NAFLD) and their association to the disease severity.

DESIGN

Twenty-two postmenopausal women with biopsy-proven NAFLD and 18 matched controls were recruited. Blood samples for serum SHBG, total testosterone, estradiol levels and standard biochemical tests were obtained after overnight fasting. Free androgen index (FAI), calculated free (cFT) and bioavailable testosterone were estimated by standard formulas.

RESULTS

The NAFLD group had lower serum SHBG levels and higher values of cFT, bioavailable testosterone and FAI, despite exhibiting similar to controls levels of serum total testosterone and estradiol. Serum SHBG levels (adjusted odds ratio [aOR] =0.912; 95% CI 0.854–0.973), bioavailable testosterone (aOr=1.254; 95% CI 1.0101.556) and FAI (aOr=2.567; 95% CI 1.153–5.716), but not cFT, were associated with NAFLD independently of age, body mass index (BMI) and waist circumference. Serum estradiol levels were associated with the presence of nonalcoholic steatohepatitis (NASH) independently of age, BMI and waist circumference (aOR=0.727; 95% CI 0.537–0.985).

CONCLUSIONS

Low SHBG levels and high metabolically active testosterone fractions were independently associated with NAFLD. Among NAFLD patients, serum estradiol levels were independently associated with NASH. However, these results need further validation from large-scale studies.

Key words

Estradiol Free androgen index Insulin resistance Metabolic syndrome Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis Sex hormone-binding globulin Testosterone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Polyzos SA, Kountouras J, Zavos C, 2009 Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines. Curr Mol Med 72: 299–314.CrossRefGoogle Scholar
  2. 2.
    Vernon G, Baranova A, Younossi ZM, 2011 Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 34: 274–285.CrossRefPubMedGoogle Scholar
  3. 3.
    Polyzos SA, Kountouras J, Zavos C, Deretzi G, 2012 Nonalcoholic fatty liver disease: Multimodal treatment options for a pathogenetically multiple-hit disease. J Clin Gastroenterol 46: 272–284.CrossRefPubMedGoogle Scholar
  4. 4.
    Baranova A, Tran TP, Birerdinc A, Younossi ZM, 2011 Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease. Aliment Pharmacol Ther 33: 801–814.CrossRefPubMedGoogle Scholar
  5. 5.
    Vassilatou E, Lafoyianni S, Vryonidou A, et al, 2010 Increased androgen bioavailability is associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome. Hum Reprod 25: 212–220.CrossRefPubMedGoogle Scholar
  6. 6.
    Shin JY, Kim SK, Lee MY, et al, 2011 Serum sex hormone-binding globulin levels are independently associated with nonalcoholic fatty liver disease in people with type 2 diabetes. Diabetes Res Clin Pract 94: 156–162.CrossRefPubMedGoogle Scholar
  7. 7.
    Mojiminiyi OA, Safar FH, Al RH, Diejomaoh M, 2010 Variations in alanine aminotransferase levels within the normal range predict metabolic and androgenic phenotypes in women of reproductive age. Scand J Clin Lab Invest 70: 554–560.CrossRefPubMedGoogle Scholar
  8. 8.
    Kauffman RP, Baker TE, Baker V, Kauffman MM, Castracane VD, 2010 Endocrine factors associated with non-alcoholic fatty liver disease in women with polycystic ovary syndrome: do androgens play a role? Gynecol Endocrinol 26: 39–46.CrossRefPubMedGoogle Scholar
  9. 9.
    Tian GX, Sun Y, Pang CJ, et al, 2012 Oestradiol is a protective factor for non-alcoholic fatty liver disease in healthy men. Obes Rev 13: 381–387.CrossRefPubMedGoogle Scholar
  10. 10.
    Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, Uribe M, Mendez-Sanchez N, 2010 Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann Hepatol 9: 402–409.PubMedGoogle Scholar
  11. 11.
    Tan S, Bechmann LP, Benson S, et al, 2010 Apoptotic markers indicate nonalcoholic steatohepatitis in polycystic ovary syndrome. J Clin Endocrinol Metab 95: 343–348.CrossRefPubMedGoogle Scholar
  12. 12.
    Kim S, Kwon H, Park JH, et al, 2012 A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease. BMC Gastroenterol 12: 69. doi:  https://doi.org/10.1186/1471-230X-12-69.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC, 1985 Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419.CrossRefPubMedGoogle Scholar
  14. 14.
    Vermeulen A, Verdonck L, Kaufman JM, 1999 A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 84: 3666–3672.CrossRefPubMedGoogle Scholar
  15. 15.
    Kleiner DE, Brunt EM, Van NM, et al, 2005 Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 41: 1313–1321.CrossRefPubMedGoogle Scholar
  16. 16.
    Brand JS, van dT, I, Grobbee DE, Emmelot-Vonk MH, van der Schouw YT, 2011 Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies. Int J Epidemiol 40: 189–207.CrossRefPubMedGoogle Scholar
  17. 17.
    Selva DM, Hogeveen KN, Innis SM, Hammond GL, 2007 Monosaccharide-induced lipogenesis regulates the human hepatic sex hormone-binding globulin gene. J Clin Invest 117: 3979–3987.PubMedPubMedCentralGoogle Scholar
  18. 18.
    Yasui T, Tomita J, Miyatani Y, et al, 2007 Associations of adiponectin with sex hormone-binding globulin levels in aging male and female populations. Clin Chim Acta 386: 69–75.CrossRefPubMedGoogle Scholar
  19. 19.
    Laaksonen DE, Niskanen L, Punnonen K, et al, 2003 Sex hormones, inflammation and the metabolic syndrome: a population-based study. Eur J Endocrinol 149: 601–608.CrossRefPubMedGoogle Scholar
  20. 20.
    McKenzie J, Fisher BM, Jaap AJ, Stanley A, Paterson K, Sattar N, 2006 Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. Clin Endocrinol (Oxf) 65: 40–44.CrossRefGoogle Scholar
  21. 21.
    Kim MH, Kang KS, Lee YS, 2010 The inhibitory effect of genistein on hepatic steatosis is linked to visceral adipocyte metabolism in mice with diet-induced nonalcoholic fatty liver disease. Br J Nutr 104: 1333–1342.CrossRefPubMedGoogle Scholar
  22. 22.
    Kamada Y, Kiso S, Yoshida Y, et al, 2011 Estrogen deficiency worsens steatohepatitis in mice fed high-fat and high-cholesterol diet. Am J Physiol Gastrointest Liver Physiol 301: G1031–G1043.CrossRefPubMedGoogle Scholar
  23. 23.
    Fukui M, Senmaru T, Hasegawa G, et al, 2011 17beta-Estradiol attenuates saturated fatty acid diet-induced liver injury in ovariectomized mice by up-regulating hepatic senescence marker protein-30. Biochem Biophys Res Commun 415: 252–257.CrossRefPubMedGoogle Scholar
  24. 24.
    Chow JD, Jones ME, Prelle K, Simpson ER, Boon WC, 2011 A selective estrogen receptor alpha agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J Endocrinol 210: 323–334.CrossRefPubMedGoogle Scholar
  25. 25.
    Giannitrapani L, Soresi M, La SE, Cervello M, D’Alessandro N, Montalto G, 2006 Sex hormones and risk of liver tumor. Ann N Y Acad Sci 1089: 228–236.CrossRefPubMedGoogle Scholar
  26. 26.
    Kountouras J, Boura P, Karolides A, Zaharioudaki E, Tsapas G, 1995 Recombinant a2 interferon (a-IFN) with chemo-hormonal therapy in patients with hepatocellular carcinoma (HCC). Hepatogastroenterology 42: 31–36.PubMedGoogle Scholar
  27. 27.
    Yin PH, Lee HC, Chau GY, et al, 2004 Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett 212: 195–201.CrossRefPubMedGoogle Scholar
  28. 28.
    Koehler E, Swain J, Sanderson S, Krishnan A, Watt K, Charlton M, 2012 Growth hormone, dehydroepiandrosterone and adiponectin levels in non-alcoholic steatohepatitis: an endocrine signature for advanced fibrosis in obese patients. Liver Int 32: 279–286.CrossRefPubMedGoogle Scholar
  29. 29.
    Sumida Y, Yonei Y, Kanemasa K, et al, 2010 Lower circulating levels of dehydroepiandrosterone, independent of insulin resistance, is an important determinant of severity of non-alcoholic steatohepatitis in Japanese patients. Hepatol Res 40: 901–910.CrossRefPubMedGoogle Scholar
  30. 30.
    Charlton M, Angulo P, Chalasani N, et al, 2008 Low circulating levels of dehydroepiandrosterone in histologically advanced nonalcoholic fatty liver disease. Hepatology 47: 484–492.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ahmed A, Rabbitt E, Brady T, et al, 2012 A switch in hepatic cortisol metabolism across the spectrum of non alcoholic fatty liver disease. PLos One 7: e29531.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Konopelska S, Kienitz T, Hughes B, et al, 2009 Hepatic 11beta-HSD1 mRNA expression in fatty liver and nonalcoholic steatohepatitis. Clin Endocrinol (Oxf) 70: 554–560.CrossRefGoogle Scholar
  33. 33.
    Bedogni G, Bellentani S, Miglioli L, et al, 2006 The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol 6: 33.CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Vongsuvanh R, George J, McLeod D, van der PD, 2012 Visceral adiposity index is not a predictor of liver histology in patients with non-alcoholic fatty liver disease. J Hepatol 57: 392–398.CrossRefPubMedGoogle Scholar
  35. 35.
    Ly LP, Sartorius G, Hull L, et al, 2010 Accuracy of calculated free testosterone formulae in men. Clin Endocrinol (Oxf) 73: 382–388.CrossRefGoogle Scholar

Copyright information

© Hellenic Endocrine Society 2013

Authors and Affiliations

  • Stergios A. Polyzos
    • 1
    Email author
  • Jannis Kountouras
    • 1
  • Agathocles Tsatsoulis
    • 2
  • Efthimia Zafeiriadou
    • 3
  • Evangelia Katsiki
    • 4
  • Kalliopi Patsiaoura
    • 4
  • Christos Zavos
    • 1
  • Vasiliki V. Anastasiadou
    • 5
  • Aristidis Slavakis
    • 6
  1. 1.Department of Medicine, Second Medical ClinicAristotle University of Thessaloniki, Ippokration HospitalThessalonikiGreece
  2. 2.Department of EndocrinologyUniversity of IoanninaIoanninaGreece
  3. 3.Department of RadiologyIppokration HospitalThessalonikiGreece
  4. 4.Department of PathologyIppokration HospitalThessalonikiGreece
  5. 5.Department of Gynecology and ObstetricsMaternity Hospital “Mitera”AthensGreece
  6. 6.Department of BiochemistryIppokration HospitalThessalonikiGreece

Personalised recommendations